China Diplomat Warns Biden to Tread Carefully on Taiwan

Business Wire
Global Facilities Management Market Report 2021: Market to Reach $3 Trillion by 2027 - U.S. Market is Estimated at $417.7 Billion, While China is Forecast to Grow at 10.8% CAGR - ResearchAndMarkets.com
The "Facilities Management - Global Market Trajectory & Analytics" report has been added to ResearchAndMarkets.com's offering.
a minute ago
Business Wire
General James Mattis to Headline Cloud Security Alliance CISO Summit at RSA Conference 2021
Virtual CSA CISO Summit at RSAC 2021 will explore critical cloud-centric IT strategies enterprises must have to succeed in the race to the cloud.
a minute ago
Business Wire
Acrisure Creates Large Relationships Division
Acrisure, a top-10 global insurance broker and fintech services provider, announced the addition of Doug Hodo, Jr. as Director of Large Relationships.
a minute ago
Business Wire
Global Granite, Marble and Stone Market Report 2021: Asia-Pacific - The Dominant and the Fastest Growing Crushed Stone Market Worldwide - ResearchAndMarkets.com
The "Granite, Marble and Stone - Global Market Trajectory & Analytics" report has been added to ResearchAndMarkets.com's offering.
2 minutes ago
GlobeNewswire
Excellthera and Ossium Health Announce a Collaboration to Advance Their Technologies and Platforms to Improve Human Health
MONTREAL, April 21, 2021 (GLOBE NEWSWIRE) -- ExCellThera Inc., a clinical-stage cell and molecular medicine company delivering molecules and bioengineering solutions to expand stem and immune cells for therapeutic use, and Ossium Health, a therapeutics company harnessing the power of stem cell science to improve treatment for patients with blood and immune diseases, announced today a collaboration agreement to evaluate and advance opportunities to combine their capabilities to further the goal of improving human health. The collaboration plans to evaluate and advance opportunities to employ adult stem cells from deceased donors from Ossium Health’s first-in-the-world bone marrow bank in conjunction with ExCellThera’s ECT-001 cell expansion and rejuvenation technology, comprised of the UM171 small molecule and an optimized culture system, to treat blood cancers, improve solid organ tolerization and repair damage from radiation. “There is deep alignment between ExCellThera and Ossium’s biotechnology platforms. We see immense potential in this new collaboration to build capacity and leverage complimentary expertise toward realizing a shared goal of improving outcomes for patients through regenerative medicine,” said Dr. Guy Sauvageau, CEO and Founder of ExCellThera. “Ossium’s world first bone marrow bank combined with ExCellThera’s cell expansion and rejuvenation technology could create an invaluable new source of expanded and rejuvenated stem cells and bring the life-saving benefits of cell therapies to patients across the globe,” said Ossium Co-Founder, President and CEO, Kevin Caldwell. About ExCellThera Inc.ExCellThera is a clinical-stage cell and molecular medicine company delivering molecules and bioengineering solutions to expand stem and immune cells for use in novel one-time curative therapies for patients with hematologic malignancies and other diseases. ExCellThera’s most advanced technology, ECT-001 Cell Therapy, combines a proprietary small molecule, UM171, and an optimized culture system. In pursuit of better treatments for patients, the company is building out its portfolio of products, as well as supporting best-in-class clinical trials. excellthera.com About Ossium HealthOssium Health is a therapeutics company that leverages its unique deceased donor bone marrow banking platform to develop stem cell therapies for patients with life-threatening blood and immune diseases. Founded in 2016, the company is run by its Co-Founder, President & CEO Kevin Caldwell, and its Co-Founder, EVP & Chief Science Officer Erik Woods. The company’s mission is “to deploy cellular therapeutics and bioengineering to produce lasting gains in the health, vitality, and longevity of human beings.” Ossium is a Public Benefit Corporation. Learn more about Ossium at www.ossiumhealth.com. CONTACT: Contacts: Investor inquiries David Millette Chief Operating and Financial Officer, ExCellThera david.millette@excellthera.com Media inquiries Lisa Willemse Chief Marketing Officer, ExCellThera lisa.willemse@excellthera.com
2 minutes ago
GlobeNewswire
Senzing One-Day Proof of Concept Finds Duplicate Data, Hidden Relationships
Demonstrates Unprecedented Entity Resolution Accuracy, Ease of Use, AffordabilityLAS VEGAS, April 21, 2021 (GLOBE NEWSWIRE) -- Entity resolution systems used to be expensive to deploy and take months to tune and train. This all changed when Senzing Inc. introduced its API-based artificial intelligence for entity resolution. Senzing is now making it even easier for developers to evaluate entity resolution. The new Senzing One-Day Proof of Concept (PoC) program, announced today, allows organizations to resolve up to 10 million records, at no charge for software or support, and quickly detect duplicates and hidden relationships about people and organizations within their data. “It used to take weeks or months to evaluate entity resolution accuracy, but now our one-day PoC delivers results in about six hours,” said Jeff Jonas, Senzing CEO. “Organizations will be blown away by how easy, accurate and affordable Senzing entity resolution is to deploy and use, especially when compared to other commercial or homegrown entity resolution systems.” With the Senzing One-Day PoC, developers resolve records in their Amazon Web Services or on-premises infrastructure. No private data ever flows to Senzing. Simple reporting tools make it easy to compare the Senzing results to those of existing systems. Most organizations will see significant improvements in accuracy from Senzing entity resolution, especially with large volumes of diverse and complex data. For more information or to get started, visit senzing.com/poc. About SenzingSenzing is the first to deliver real‐time, artificial intelligence for entity resolution. Senzing software enables organizations of all sizes to gain highly accurate and valuable insights about who is who and who is related to whom in data. The Senzing APIs make it easy for software developers to quickly and affordably build scalable entity resolution into applications and data services. With Senzing, innovators in financial services, information services, healthcare, public sector and other industries can more effectively engage with customers, improve fraud detection, optimize investigative analysis, and increase accuracy for compliance mandates. To learn more, visit senzing.com or follow us on Twitter and LinkedIn. SENZING is a registered trademark of Senzing, Inc. and may not be used without prior written permission. Media Contact:Susan Spencersusan@senzing.com(424) 247-6588
2 minutes ago
GlobeNewswire
Global Transcatheter Pulmonary Valves Market to Reach $58.6 Million by 2027
Abstract: - Global Transcatheter Pulmonary Valves Market to Reach $58. 6 Million by 2027. - Amid the COVID-19 crisis, the global market for Transcatheter Pulmonary Valves estimated at US$39.New York, April 21, 2021 (GLOBE NEWSWIRE) -- Reportlinker.com announces the release of the report "Global Transcatheter Pulmonary Valves Industry" - https://www.reportlinker.com/p06033159/?utm_source=GNW 8 Million in the year 2020, is projected to reach a revised size of US$58.6 Million by 2027, growing at aCAGR of 5.7% over the period 2020-2027. Balloon-Expanded, one of the segments analyzed in the report, is projected to record 5.6% CAGR and reach US$36.2 Million by the end of the analysis period. After an early analysis of the business implications of the pandemic and its induced economic crisis, growth in the Self-Expanded segment is readjusted to a revised 5.8% CAGR for the next 7-year period. - The U.S. Market is Estimated at $10.7 Million, While China is Forecast to Grow at 9.2% CAGR - The Transcatheter Pulmonary Valves market in the U.S. is estimated at US$10.7 Million in the year 2020. China, the world`s second largest economy, is forecast to reach a projected market size of US$12.8 Million by the year 2027 trailing a CAGR of 9.2% over the analysis period 2020 to 2027. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 3.1% and 4.5% respectively over the 2020-2027 period. Within Europe, Germany is forecast to grow at approximately 4% CAGR. - Select Competitors (Total 42 Featured) - Boston Scientific CorporationBraile BiomedicaColibri Heart Valve LLCCryolife Inc.Direct Flow Medical Inc.Edward Lifesciences CorporationJenavalve Technology Inc.Livanova plcMedtronicSt. Jude MedicalVenus Medtech Read the full report: https://www.reportlinker.com/p06033159/?utm_source=GNW I. METHODOLOGY II. EXECUTIVE SUMMARY 1. MARKET OVERVIEW Influencer Market Insights World Market Trajectories Impact of Covid-19 and a Looming Global Recession 2. FOCUS ON SELECT PLAYERS 3. MARKET TRENDS & DRIVERS 4. GLOBAL MARKET PERSPECTIVE Table 1: World Current & Future Analysis for Transcatheter Pulmonary Valves by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2020 through 2027 and % CAGR Table 2: World Historic Review for Transcatheter Pulmonary Valves by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2012 through 2019 and % CAGR Table 3: World 15-Year Perspective for Transcatheter Pulmonary Valves by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2012, 2020 & 2027 Table 4: World Current & Future Analysis for Balloon-Expanded by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2020 through 2027 and % CAGR Table 5: World Historic Review for Balloon-Expanded by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2012 through 2019 and % CAGR Table 6: World 15-Year Perspective for Balloon-Expanded by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2012, 2020 & 2027 Table 7: World Current & Future Analysis for Self-Expanded by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2020 through 2027 and % CAGR Table 8: World Historic Review for Self-Expanded by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2012 through 2019 and % CAGR Table 9: World 15-Year Perspective for Self-Expanded by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2012, 2020 & 2027 Table 10: World Current & Future Analysis for Tissue Engineered by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2020 through 2027 and % CAGR Table 11: World Historic Review for Tissue Engineered by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2012 through 2019 and % CAGR Table 12: World 15-Year Perspective for Tissue Engineered by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2012, 2020 & 2027 Table 13: World Current & Future Analysis for Synthetic by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2020 through 2027 and % CAGR Table 14: World Historic Review for Synthetic by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2012 through 2019 and % CAGR Table 15: World 15-Year Perspective for Synthetic by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2012, 2020 & 2027 Table 16: World Current & Future Analysis for Adult by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2020 through 2027 and % CAGR Table 17: World Historic Review for Adult by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2012 through 2019 and % CAGR Table 18: World 15-Year Perspective for Adult by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2012, 2020 & 2027 Table 19: World Current & Future Analysis for Pediatric by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2020 through 2027 and % CAGR Table 20: World Historic Review for Pediatric by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2012 through 2019 and % CAGR Table 21: World 15-Year Perspective for Pediatric by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2012, 2020 & 2027 III. MARKET ANALYSIS UNITED STATES Table 22: USA Current & Future Analysis for Transcatheter Pulmonary Valves by Technology - Balloon-Expanded and Self-Expanded - Independent Analysis of Annual Sales in US$ for the Years 2020 through 2027 and % CAGR Table 23: USA Historic Review for Transcatheter Pulmonary Valves by Technology - Balloon-Expanded and Self-Expanded Markets - Independent Analysis of Annual Sales in US$ for Years 2012 through 2019 and % CAGR Table 24: USA 15-Year Perspective for Transcatheter Pulmonary Valves by Technology - Percentage Breakdown of Value Sales for Balloon-Expanded and Self-Expanded for the Years 2012, 2020 & 2027 Table 25: USA Current & Future Analysis for Transcatheter Pulmonary Valves by Material Type - Tissue Engineered and Synthetic - Independent Analysis of Annual Sales in US$ for the Years 2020 through 2027 and % CAGR Table 26: USA Historic Review for Transcatheter Pulmonary Valves by Material Type - Tissue Engineered and Synthetic Markets - Independent Analysis of Annual Sales in US$ for Years 2012 through 2019 and % CAGR Table 27: USA 15-Year Perspective for Transcatheter Pulmonary Valves by Material Type - Percentage Breakdown of Value Sales for Tissue Engineered and Synthetic for the Years 2012, 2020 & 2027 Table 28: USA Current & Future Analysis for Transcatheter Pulmonary Valves by End-Use - Adult and Pediatric - Independent Analysis of Annual Sales in US$ for the Years 2020 through 2027 and % CAGR Table 29: USA Historic Review for Transcatheter Pulmonary Valves by End-Use - Adult and Pediatric Markets - Independent Analysis of Annual Sales in US$ for Years 2012 through 2019 and % CAGR Table 30: USA 15-Year Perspective for Transcatheter Pulmonary Valves by End-Use - Percentage Breakdown of Value Sales for Adult and Pediatric for the Years 2012, 2020 & 2027 CANADA Table 31: Canada Current & Future Analysis for Transcatheter Pulmonary Valves by Technology - Balloon-Expanded and Self-Expanded - Independent Analysis of Annual Sales in US$ for the Years 2020 through 2027 and % CAGR Table 32: Canada Historic Review for Transcatheter Pulmonary Valves by Technology - Balloon-Expanded and Self-Expanded Markets - Independent Analysis of Annual Sales in US$ for Years 2012 through 2019 and % CAGR Table 33: Canada 15-Year Perspective for Transcatheter Pulmonary Valves by Technology - Percentage Breakdown of Value Sales for Balloon-Expanded and Self-Expanded for the Years 2012, 2020 & 2027 Table 34: Canada Current & Future Analysis for Transcatheter Pulmonary Valves by Material Type - Tissue Engineered and Synthetic - Independent Analysis of Annual Sales in US$ for the Years 2020 through 2027 and % CAGR Table 35: Canada Historic Review for Transcatheter Pulmonary Valves by Material Type - Tissue Engineered and Synthetic Markets - Independent Analysis of Annual Sales in US$ for Years 2012 through 2019 and % CAGR Table 36: Canada 15-Year Perspective for Transcatheter Pulmonary Valves by Material Type - Percentage Breakdown of Value Sales for Tissue Engineered and Synthetic for the Years 2012, 2020 & 2027 Table 37: Canada Current & Future Analysis for Transcatheter Pulmonary Valves by End-Use - Adult and Pediatric - Independent Analysis of Annual Sales in US$ for the Years 2020 through 2027 and % CAGR Table 38: Canada Historic Review for Transcatheter Pulmonary Valves by End-Use - Adult and Pediatric Markets - Independent Analysis of Annual Sales in US$ for Years 2012 through 2019 and % CAGR Table 39: Canada 15-Year Perspective for Transcatheter Pulmonary Valves by End-Use - Percentage Breakdown of Value Sales for Adult and Pediatric for the Years 2012, 2020 & 2027 JAPAN Table 40: Japan Current & Future Analysis for Transcatheter Pulmonary Valves by Technology - Balloon-Expanded and Self-Expanded - Independent Analysis of Annual Sales in US$ for the Years 2020 through 2027 and % CAGR Table 41: Japan Historic Review for Transcatheter Pulmonary Valves by Technology - Balloon-Expanded and Self-Expanded Markets - Independent Analysis of Annual Sales in US$ for Years 2012 through 2019 and % CAGR Table 42: Japan 15-Year Perspective for Transcatheter Pulmonary Valves by Technology - Percentage Breakdown of Value Sales for Balloon-Expanded and Self-Expanded for the Years 2012, 2020 & 2027 Table 43: Japan Current & Future Analysis for Transcatheter Pulmonary Valves by Material Type - Tissue Engineered and Synthetic - Independent Analysis of Annual Sales in US$ for the Years 2020 through 2027 and % CAGR Table 44: Japan Historic Review for Transcatheter Pulmonary Valves by Material Type - Tissue Engineered and Synthetic Markets - Independent Analysis of Annual Sales in US$ for Years 2012 through 2019 and % CAGR Table 45: Japan 15-Year Perspective for Transcatheter Pulmonary Valves by Material Type - Percentage Breakdown of Value Sales for Tissue Engineered and Synthetic for the Years 2012, 2020 & 2027 Table 46: Japan Current & Future Analysis for Transcatheter Pulmonary Valves by End-Use - Adult and Pediatric - Independent Analysis of Annual Sales in US$ for the Years 2020 through 2027 and % CAGR Table 47: Japan Historic Review for Transcatheter Pulmonary Valves by End-Use - Adult and Pediatric Markets - Independent Analysis of Annual Sales in US$ for Years 2012 through 2019 and % CAGR Table 48: Japan 15-Year Perspective for Transcatheter Pulmonary Valves by End-Use - Percentage Breakdown of Value Sales for Adult and Pediatric for the Years 2012, 2020 & 2027 CHINA Table 49: China Current & Future Analysis for Transcatheter Pulmonary Valves by Technology - Balloon-Expanded and Self-Expanded - Independent Analysis of Annual Sales in US$ for the Years 2020 through 2027 and % CAGR Table 50: China Historic Review for Transcatheter Pulmonary Valves by Technology - Balloon-Expanded and Self-Expanded Markets - Independent Analysis of Annual Sales in US$ for Years 2012 through 2019 and % CAGR Table 51: China 15-Year Perspective for Transcatheter Pulmonary Valves by Technology - Percentage Breakdown of Value Sales for Balloon-Expanded and Self-Expanded for the Years 2012, 2020 & 2027 Table 52: China Current & Future Analysis for Transcatheter Pulmonary Valves by Material Type - Tissue Engineered and Synthetic - Independent Analysis of Annual Sales in US$ for the Years 2020 through 2027 and % CAGR Table 53: China Historic Review for Transcatheter Pulmonary Valves by Material Type - Tissue Engineered and Synthetic Markets - Independent Analysis of Annual Sales in US$ for Years 2012 through 2019 and % CAGR Table 54: China 15-Year Perspective for Transcatheter Pulmonary Valves by Material Type - Percentage Breakdown of Value Sales for Tissue Engineered and Synthetic for the Years 2012, 2020 & 2027 Table 55: China Current & Future Analysis for Transcatheter Pulmonary Valves by End-Use - Adult and Pediatric - Independent Analysis of Annual Sales in US$ for the Years 2020 through 2027 and % CAGR Table 56: China Historic Review for Transcatheter Pulmonary Valves by End-Use - Adult and Pediatric Markets - Independent Analysis of Annual Sales in US$ for Years 2012 through 2019 and % CAGR Table 57: China 15-Year Perspective for Transcatheter Pulmonary Valves by End-Use - Percentage Breakdown of Value Sales for Adult and Pediatric for the Years 2012, 2020 & 2027 EUROPE Table 58: Europe Current & Future Analysis for Transcatheter Pulmonary Valves by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ for Years 2020 through 2027 and % CAGR Table 59: Europe Historic Review for Transcatheter Pulmonary Valves by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ for Years 2012 through 2019 and % CAGR Table 60: Europe 15-Year Perspective for Transcatheter Pulmonary Valves by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2012, 2020 & 2027 Table 61: Europe Current & Future Analysis for Transcatheter Pulmonary Valves by Technology - Balloon-Expanded and Self-Expanded - Independent Analysis of Annual Sales in US$ for the Years 2020 through 2027 and % CAGR Table 62: Europe Historic Review for Transcatheter Pulmonary Valves by Technology - Balloon-Expanded and Self-Expanded Markets - Independent Analysis of Annual Sales in US$ for Years 2012 through 2019 and % CAGR Table 63: Europe 15-Year Perspective for Transcatheter Pulmonary Valves by Technology - Percentage Breakdown of Value Sales for Balloon-Expanded and Self-Expanded for the Years 2012, 2020 & 2027 Table 64: Europe Current & Future Analysis for Transcatheter Pulmonary Valves by Material Type - Tissue Engineered and Synthetic - Independent Analysis of Annual Sales in US$ for the Years 2020 through 2027 and % CAGR Table 65: Europe Historic Review for Transcatheter Pulmonary Valves by Material Type - Tissue Engineered and Synthetic Markets - Independent Analysis of Annual Sales in US$ for Years 2012 through 2019 and % CAGR Table 66: Europe 15-Year Perspective for Transcatheter Pulmonary Valves by Material Type - Percentage Breakdown of Value Sales for Tissue Engineered and Synthetic for the Years 2012, 2020 & 2027 Table 67: Europe Current & Future Analysis for Transcatheter Pulmonary Valves by End-Use - Adult and Pediatric - Independent Analysis of Annual Sales in US$ for the Years 2020 through 2027 and % CAGR Table 68: Europe Historic Review for Transcatheter Pulmonary Valves by End-Use - Adult and Pediatric Markets - Independent Analysis of Annual Sales in US$ for Years 2012 through 2019 and % CAGR Table 69: Europe 15-Year Perspective for Transcatheter Pulmonary Valves by End-Use - Percentage Breakdown of Value Sales for Adult and Pediatric for the Years 2012, 2020 & 2027 FRANCE Table 70: France Current & Future Analysis for Transcatheter Pulmonary Valves by Technology - Balloon-Expanded and Self-Expanded - Independent Analysis of Annual Sales in US$ for the Years 2020 through 2027 and % CAGR Table 71: France Historic Review for Transcatheter Pulmonary Valves by Technology - Balloon-Expanded and Self-Expanded Markets - Independent Analysis of Annual Sales in US$ for Years 2012 through 2019 and % CAGR Table 72: France 15-Year Perspective for Transcatheter Pulmonary Valves by Technology - Percentage Breakdown of Value Sales for Balloon-Expanded and Self-Expanded for the Years 2012, 2020 & 2027 Table 73: France Current & Future Analysis for Transcatheter Pulmonary Valves by Material Type - Tissue Engineered and Synthetic - Independent Analysis of Annual Sales in US$ for the Years 2020 through 2027 and % CAGR Table 74: France Historic Review for Transcatheter Pulmonary Valves by Material Type - Tissue Engineered and Synthetic Markets - Independent Analysis of Annual Sales in US$ for Years 2012 through 2019 and % CAGR Table 75: France 15-Year Perspective for Transcatheter Pulmonary Valves by Material Type - Percentage Breakdown of Value Sales for Tissue Engineered and Synthetic for the Years 2012, 2020 & 2027 Table 76: France Current & Future Analysis for Transcatheter Pulmonary Valves by End-Use - Adult and Pediatric - Independent Analysis of Annual Sales in US$ for the Years 2020 through 2027 and % CAGR Table 77: France Historic Review for Transcatheter Pulmonary Valves by End-Use - Adult and Pediatric Markets - Independent Analysis of Annual Sales in US$ for Years 2012 through 2019 and % CAGR Table 78: France 15-Year Perspective for Transcatheter Pulmonary Valves by End-Use - Percentage Breakdown of Value Sales for Adult and Pediatric for the Years 2012, 2020 & 2027 GERMANY Table 79: Germany Current & Future Analysis for Transcatheter Pulmonary Valves by Technology - Balloon-Expanded and Self-Expanded - Independent Analysis of Annual Sales in US$ for the Years 2020 through 2027 and % CAGR Table 80: Germany Historic Review for Transcatheter Pulmonary Valves by Technology - Balloon-Expanded and Self-Expanded Markets - Independent Analysis of Annual Sales in US$ for Years 2012 through 2019 and % CAGR Table 81: Germany 15-Year Perspective for Transcatheter Pulmonary Valves by Technology - Percentage Breakdown of Value Sales for Balloon-Expanded and Self-Expanded for the Years 2012, 2020 & 2027 Table 82: Germany Current & Future Analysis for Transcatheter Pulmonary Valves by Material Type - Tissue Engineered and Synthetic - Independent Analysis of Annual Sales in US$ for the Years 2020 through 2027 and % CAGR Table 83: Germany Historic Review for Transcatheter Pulmonary Valves by Material Type - Tissue Engineered and Synthetic Markets - Independent Analysis of Annual Sales in US$ for Years 2012 through 2019 and % CAGR Table 84: Germany 15-Year Perspective for Transcatheter Pulmonary Valves by Material Type - Percentage Breakdown of Value Sales for Tissue Engineered and Synthetic for the Years 2012, 2020 & 2027 Table 85: Germany Current & Future Analysis for Transcatheter Pulmonary Valves by End-Use - Adult and Pediatric - Independent Analysis of Annual Sales in US$ for the Years 2020 through 2027 and % CAGR Table 86: Germany Historic Review for Transcatheter Pulmonary Valves by End-Use - Adult and Pediatric Markets - Independent Analysis of Annual Sales in US$ for Years 2012 through 2019 and % CAGR Table 87: Germany 15-Year Perspective for Transcatheter Pulmonary Valves by End-Use - Percentage Breakdown of Value Sales for Adult and Pediatric for the Years 2012, 2020 & 2027 ITALY Table 88: Italy Current & Future Analysis for Transcatheter Pulmonary Valves by Technology - Balloon-Expanded and Self-Expanded - Independent Analysis of Annual Sales in US$ for the Years 2020 through 2027 and % CAGR Table 89: Italy Historic Review for Transcatheter Pulmonary Valves by Technology - Balloon-Expanded and Self-Expanded Markets - Independent Analysis of Annual Sales in US$ for Years 2012 through 2019 and % CAGR Table 90: Italy 15-Year Perspective for Transcatheter Pulmonary Valves by Technology - Percentage Breakdown of Value Sales for Balloon-Expanded and Self-Expanded for the Years 2012, 2020 & 2027 Table 91: Italy Current & Future Analysis for Transcatheter Pulmonary Valves by Material Type - Tissue Engineered and Synthetic - Independent Analysis of Annual Sales in US$ for the Years 2020 through 2027 and % CAGR Table 92: Italy Historic Review for Transcatheter Pulmonary Valves by Material Type - Tissue Engineered and Synthetic Markets - Independent Analysis of Annual Sales in US$ for Years 2012 through 2019 and % CAGR Table 93: Italy 15-Year Perspective for Transcatheter Pulmonary Valves by Material Type - Percentage Breakdown of Value Sales for Tissue Engineered and Synthetic for the Years 2012, 2020 & 2027 Table 94: Italy Current & Future Analysis for Transcatheter Pulmonary Valves by End-Use - Adult and Pediatric - Independent Analysis of Annual Sales in US$ for the Years 2020 through 2027 and % CAGR Table 95: Italy Historic Review for Transcatheter Pulmonary Valves by End-Use - Adult and Pediatric Markets - Independent Analysis of Annual Sales in US$ for Years 2012 through 2019 and % CAGR Table 96: Italy 15-Year Perspective for Transcatheter Pulmonary Valves by End-Use - Percentage Breakdown of Value Sales for Adult and Pediatric for the Years 2012, 2020 & 2027 UNITED KINGDOM Table 97: UK Current & Future Analysis for Transcatheter Pulmonary Valves by Technology - Balloon-Expanded and Self-Expanded - Independent Analysis of Annual Sales in US$ for the Years 2020 through 2027 and % CAGR Table 98: UK Historic Review for Transcatheter Pulmonary Valves by Technology - Balloon-Expanded and Self-Expanded Markets - Independent Analysis of Annual Sales in US$ for Years 2012 through 2019 and % CAGR Table 99: UK 15-Year Perspective for Transcatheter Pulmonary Valves by Technology - Percentage Breakdown of Value Sales for Balloon-Expanded and Self-Expanded for the Years 2012, 2020 & 2027 Table 100: UK Current & Future Analysis for Transcatheter Pulmonary Valves by Material Type - Tissue Engineered and Synthetic - Independent Analysis of Annual Sales in US$ for the Years 2020 through 2027 and % CAGR Table 101: UK Historic Review for Transcatheter Pulmonary Valves by Material Type - Tissue Engineered and Synthetic Markets - Independent Analysis of Annual Sales in US$ for Years 2012 through 2019 and % CAGR Table 102: UK 15-Year Perspective for Transcatheter Pulmonary Valves by Material Type - Percentage Breakdown of Value Sales for Tissue Engineered and Synthetic for the Years 2012, 2020 & 2027 Table 103: UK Current & Future Analysis for Transcatheter Pulmonary Valves by End-Use - Adult and Pediatric - Independent Analysis of Annual Sales in US$ for the Years 2020 through 2027 and % CAGR Table 104: UK Historic Review for Transcatheter Pulmonary Valves by End-Use - Adult and Pediatric Markets - Independent Analysis of Annual Sales in US$ for Years 2012 through 2019 and % CAGR Table 105: UK 15-Year Perspective for Transcatheter Pulmonary Valves by End-Use - Percentage Breakdown of Value Sales for Adult and Pediatric for the Years 2012, 2020 & 2027 SPAIN Table 106: Spain Current & Future Analysis for Transcatheter Pulmonary Valves by Technology - Balloon-Expanded and Self-Expanded - Independent Analysis of Annual Sales in US$ for the Years 2020 through 2027 and % CAGR Table 107: Spain Historic Review for Transcatheter Pulmonary Valves by Technology - Balloon-Expanded and Self-Expanded Markets - Independent Analysis of Annual Sales in US$ for Years 2012 through 2019 and % CAGR Table 108: Spain 15-Year Perspective for Transcatheter Pulmonary Valves by Technology - Percentage Breakdown of Value Sales for Balloon-Expanded and Self-Expanded for the Years 2012, 2020 & 2027 Table 109: Spain Current & Future Analysis for Transcatheter Pulmonary Valves by Material Type - Tissue Engineered and Synthetic - Independent Analysis of Annual Sales in US$ for the Years 2020 through 2027 and % CAGR Table 110: Spain Historic Review for Transcatheter Pulmonary Valves by Material Type - Tissue Engineered and Synthetic Markets - Independent Analysis of Annual Sales in US$ for Years 2012 through 2019 and % CAGR Table 111: Spain 15-Year Perspective for Transcatheter Pulmonary Valves by Material Type - Percentage Breakdown of Value Sales for Tissue Engineered and Synthetic for the Years 2012, 2020 & 2027 Table 112: Spain Current & Future Analysis for Transcatheter Pulmonary Valves by End-Use - Adult and Pediatric - Independent Analysis of Annual Sales in US$ for the Years 2020 through 2027 and % CAGR Table 113: Spain Historic Review for Transcatheter Pulmonary Valves by End-Use - Adult and Pediatric Markets - Independent Analysis of Annual Sales in US$ for Years 2012 through 2019 and % CAGR Table 114: Spain 15-Year Perspective for Transcatheter Pulmonary Valves by End-Use - Percentage Breakdown of Value Sales for Adult and Pediatric for the Years 2012, 2020 & 2027 RUSSIA Table 115: Russia Current & Future Analysis for Transcatheter Pulmonary Valves by Technology - Balloon-Expanded and Self-Expanded - Independent Analysis of Annual Sales in US$ for the Years 2020 through 2027 and % CAGR Table 116: Russia Historic Review for Transcatheter Pulmonary Valves by Technology - Balloon-Expanded and Self-Expanded Markets - Independent Analysis of Annual Sales in US$ for Years 2012 through 2019 and % CAGR Table 117: Russia 15-Year Perspective for Transcatheter Pulmonary Valves by Technology - Percentage Breakdown of Value Sales for Balloon-Expanded and Self-Expanded for the Years 2012, 2020 & 2027 Table 118: Russia Current & Future Analysis for Transcatheter Pulmonary Valves by Material Type - Tissue Engineered and Synthetic - Independent Analysis of Annual Sales in US$ for the Years 2020 through 2027 and % CAGR Table 119: Russia Historic Review for Transcatheter Pulmonary Valves by Material Type - Tissue Engineered and Synthetic Markets - Independent Analysis of Annual Sales in US$ for Years 2012 through 2019 and % CAGR Table 120: Russia 15-Year Perspective for Transcatheter Pulmonary Valves by Material Type - Percentage Breakdown of Value Sales for Tissue Engineered and Synthetic for the Years 2012, 2020 & 2027 Table 121: Russia Current & Future Analysis for Transcatheter Pulmonary Valves by End-Use - Adult and Pediatric - Independent Analysis of Annual Sales in US$ for the Years 2020 through 2027 and % CAGR Table 122: Russia Historic Review for Transcatheter Pulmonary Valves by End-Use - Adult and Pediatric Markets - Independent Analysis of Annual Sales in US$ for Years 2012 through 2019 and % CAGR Table 123: Russia 15-Year Perspective for Transcatheter Pulmonary Valves by End-Use - Percentage Breakdown of Value Sales for Adult and Pediatric for the Years 2012, 2020 & 2027 REST OF EUROPE Table 124: Rest of Europe Current & Future Analysis for Transcatheter Pulmonary Valves by Technology - Balloon-Expanded and Self-Expanded - Independent Analysis of Annual Sales in US$ for the Years 2020 through 2027 and % CAGR Table 125: Rest of Europe Historic Review for Transcatheter Pulmonary Valves by Technology - Balloon-Expanded and Self-Expanded Markets - Independent Analysis of Annual Sales in US$ for Years 2012 through 2019 and % CAGR Table 126: Rest of Europe 15-Year Perspective for Transcatheter Pulmonary Valves by Technology - Percentage Breakdown of Value Sales for Balloon-Expanded and Self-Expanded for the Years 2012, 2020 & 2027 Table 127: Rest of Europe Current & Future Analysis for Transcatheter Pulmonary Valves by Material Type - Tissue Engineered and Synthetic - Independent Analysis of Annual Sales in US$ for the Years 2020 through 2027 and % CAGR Table 128: Rest of Europe Historic Review for Transcatheter Pulmonary Valves by Material Type - Tissue Engineered and Synthetic Markets - Independent Analysis of Annual Sales in US$ for Years 2012 through 2019 and % CAGR Table 129: Rest of Europe 15-Year Perspective for Transcatheter Pulmonary Valves by Material Type - Percentage Breakdown of Value Sales for Tissue Engineered and Synthetic for the Years 2012, 2020 & 2027 Table 130: Rest of Europe Current & Future Analysis for Transcatheter Pulmonary Valves by End-Use - Adult and Pediatric - Independent Analysis of Annual Sales in US$ for the Years 2020 through 2027 and % CAGR Table 131: Rest of Europe Historic Review for Transcatheter Pulmonary Valves by End-Use - Adult and Pediatric Markets - Independent Analysis of Annual Sales in US$ for Years 2012 through 2019 and % CAGR Table 132: Rest of Europe 15-Year Perspective for Transcatheter Pulmonary Valves by End-Use - Percentage Breakdown of Value Sales for Adult and Pediatric for the Years 2012, 2020 & 2027 ASIA-PACIFIC Table 133: Asia-Pacific Current & Future Analysis for Transcatheter Pulmonary Valves by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ for Years 2020 through 2027 and % CAGR Table 134: Asia-Pacific Historic Review for Transcatheter Pulmonary Valves by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ for Years 2012 through 2019 and % CAGR Table 135: Asia-Pacific 15-Year Perspective for Transcatheter Pulmonary Valves by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2012, 2020 & 2027 Table 136: Asia-Pacific Current & Future Analysis for Transcatheter Pulmonary Valves by Technology - Balloon-Expanded and Self-Expanded - Independent Analysis of Annual Sales in US$ for the Years 2020 through 2027 and % CAGR Table 137: Asia-Pacific Historic Review for Transcatheter Pulmonary Valves by Technology - Balloon-Expanded and Self-Expanded Markets - Independent Analysis of Annual Sales in US$ for Years 2012 through 2019 and % CAGR Table 138: Asia-Pacific 15-Year Perspective for Transcatheter Pulmonary Valves by Technology - Percentage Breakdown of Value Sales for Balloon-Expanded and Self-Expanded for the Years 2012, 2020 & 2027 Table 139: Asia-Pacific Current & Future Analysis for Transcatheter Pulmonary Valves by Material Type - Tissue Engineered and Synthetic - Independent Analysis of Annual Sales in US$ for the Years 2020 through 2027 and % CAGR Table 140: Asia-Pacific Historic Review for Transcatheter Pulmonary Valves by Material Type - Tissue Engineered and Synthetic Markets - Independent Analysis of Annual Sales in US$ for Years 2012 through 2019 and % CAGR Table 141: Asia-Pacific 15-Year Perspective for Transcatheter Pulmonary Valves by Material Type - Percentage Breakdown of Value Sales for Tissue Engineered and Synthetic for the Years 2012, 2020 & 2027 Table 142: Asia-Pacific Current & Future Analysis for Transcatheter Pulmonary Valves by End-Use - Adult and Pediatric - Independent Analysis of Annual Sales in US$ for the Years 2020 through 2027 and % CAGR Table 143: Asia-Pacific Historic Review for Transcatheter Pulmonary Valves by End-Use - Adult and Pediatric Markets - Independent Analysis of Annual Sales in US$ for Years 2012 through 2019 and % CAGR Table 144: Asia-Pacific 15-Year Perspective for Transcatheter Pulmonary Valves by End-Use - Percentage Breakdown of Value Sales for Adult and Pediatric for the Years 2012, 2020 & 2027 AUSTRALIA Table 145: Australia Current & Future Analysis for Transcatheter Pulmonary Valves by Technology - Balloon-Expanded and Self-Expanded - Independent Analysis of Annual Sales in US$ for the Years 2020 through 2027 and % CAGR Table 146: Australia Historic Review for Transcatheter Pulmonary Valves by Technology - Balloon-Expanded and Self-Expanded Markets - Independent Analysis of Annual Sales in US$ for Years 2012 through 2019 and % CAGR Table 147: Australia 15-Year Perspective for Transcatheter Please contact our Customer Support Center to get the complete Table of ContentsRead the full report: https://www.reportlinker.com/p06033159/?utm_source=GNWAbout ReportlinkerReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place.__________________________ CONTACT: Clare: clare@reportlinker.com US: (339)-368-6001 Intl: +1 339-368-6001
2 minutes ago
GlobeNewswire
Atlas Technical Consultants Awarded Engineering Services Contract with Texas Department of Transportation
AUSTIN, Texas, April 21, 2021 (GLOBE NEWSWIRE) -- Atlas Technical Consultants, Inc. (Nasdaq: ATCX) (“Atlas” or the “Company”), a leading Infrastructure and Environmental services provider, announced today that it was awarded a $2 million contract to provide engineering services for the Texas Department of Transportation (TxDOT) El Paso District. The newly awarded contract will remain in effect for a term of five years. “The Atlas team was one of two contracts awarded, and we are grateful for the longstanding partnership we have built with TxDOT for more than 20 years of working together—one that has resulted in a number of significant projects that have improved the quality of life for Texans,” said Atlas CEO L. Joe Boyer. “We will continue to enhance our suite of services in Testing, Inspection and Certification (TIC) so that we consistently provide excellence, safety and quality to TxDOT and all of our clients.” The contract includes the performance of all sampling, testing, inspection work, and related services for asphaltic, soil/flexible base, and concrete construction for the State on highway projects. TxDOT’s El Paso District maintains approximately 4,979 lane miles of highways across six counties with an annual construction and maintenance expenditure of approximately $190 Million. This is Atlas’ fourth Materials Contract with the El Paso District since 2015. The contract will be staffed with personnel from the company’s El Paso office that is comprised of engineers, inspectors, and technicians in their AASHTO resource and TxDOT accredited laboratory. Like Texas DOT, Atlas is committed to maintaining a strong safety culture and a healthy, hazard-free work environment for all who operate in, visit, or enter their facilities and job sites. About Atlas Technical ConsultantsHeadquartered in Austin, Texas, Atlas is a leading provider of Environmental (ENV), Testing, Inspection & Certification (TIC), Engineering & Design (E&D), and Program, Construction, and Quality Management (PCQM) services. Under the name Atlas Technical Consultants, we offer solutions to public and private sector clients in the transportation, commercial, water, government, education, and industrial markets. With approximately 3,300 employees and a nationwide footprint, Atlas provides a broad range of mission-critical technical services, helping clients test, inspect, certify, plan, design, and manage a wide variety of projects across diverse end markets. For more information, go to https://www.oneatlas.com. Contacts: MediaKarlene Barron770-314-5270karlene.barron@oneatlas.com Investor Relations512-851-1507ir@oneatlas.com
3 minutes ago
Motley Fool
Do You Need a Crypto Wallet to Store Your Bitcoin?
You don't need your own crypto wallet for Bitcoin, but it could make sense in some circumstances.
4 minutes ago
GlobeNewswire
InvestorBrandNetwork Announces Gamechangers LIVE Interview with Knightscope Inc. Chairman and CEO William Santana Li
LOS ANGELES, April 21, 2021 (GLOBE NEWSWIRE) -- via InvestorWire -- InvestorBrandNetwork (“IBN”), a multifaceted financial news and publishing company for private and public entities, today announces that William Santana Li, Chairman and CEO of Knightscope Inc., recently appeared on Gamechangers LIVE, a podcast series putting a spotlight on individuals who are gamechangers in their fields and sharing perspective on their journeys, mindsets, struggles and successes in an effort to inspire and inform listeners. The broadcast, hosted by Executive Coach and Speaker Sergio Tigera, is available for on-demand viewing on Gamechangers LIVE. During the interview, Li discussed how the events of September 11, 2001, have continued to motivate his founding and operation of Knightscope, which develops and builds advanced physical security technologies that are deployed through Autonomous Security Robots (ASRs), providing 24/7/365 security for a wide range of clients. “The ASRs are a unique combination of self-driving autonomous technology, robotics and artificial intelligence. They primarily do two things,” Li explained. “One, they give the two million law enforcement and security professionals in this country really smart eyes and ears and voices on the ground, so they can do their jobs more effectively. Second, they provide a physical deterrence. An ASR just being there can stop a lot of negative behavior.” “When 9/11 occurred, that’s what has pretty much driven me ever since,” he continued. “I was born in New York City. Someone hit my town on 9/11, so the rest of my life I’m dedicating to better securing our country. Crime has a $1 trillion negative economic impact on the U.S. every single year. It’s a hidden tax we all pay, so Knightscope is going to see if we can make the U.S. the safest country in the world. People think I’m kidding around, but, after eight years, they’re realizing I’m not kidding. We’re going to do this.” “The gamechanger for me was a new regulatory framework for companies to raise capital from people that care and are long-term investors. That changed what I had been doing,” Li said. “(In previous companies) I’d been backed by a major corporation. I’d been backed by venture capital. I’ve been through that process. But we’ve now raised over $70 million to build all Knightscope technology from scratch. There’s a new way to raise capital. As entrepreneurs begin to understand that, they’ll ask themselves, ‘Do I have the right kind of capital for what I’m trying to do?’.” Throughout the interview, Li described Knightscope’s business model, the security capabilities of the company’s ASRs, and the problem-solving approach that helped him become a senior executive at Ford Motor Co. by age 28. Learn more by viewing the full interview on Gamechangers LIVE. About Knightscope Inc. Knightscope is an advanced security technology company based in Silicon Valley that builds fully autonomous security robots that deter, detect and report. The company’s long-term ambition is to make the United States of America the safest country in the world. For more information, visit the company’s website at www.knightscope.com. Follow Knightscope on Facebook, Twitter, LinkedIn and Instagram. About InvestorBrandNetwork The InvestorBrandNetwork (“IBN”) consists of financial brands introduced to the investment public over the course of 15+ years. With IBN, we have amassed a collective audience of millions of social media followers. These distinctive investor brands aim to fulfill the unique needs of a growing base of client-partners. IBN will continue to expand our branded network of highly influential properties, leveraging the knowledge and energy of specialized teams of experts to serve our increasingly diversified list of clients. Through NetworkNewsWire (“NNW”) and its affiliate brands, IBN provides: (1) access to a network of wire solutions via InvestorWire to reach all target markets, industries and demographics in the most effective manner possible; (2) article and editorial syndication to 5,000+ news outlets; (3) enhanced press release solutions to ensure maximum impact; (4) full-scale distribution to a growing social media audience; (5) a full array of corporate communications solutions; and (6) a total news coverage solution. For more information on IBN, visit https://www.InvestorBrandNetwork.com Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: https://IBN.fm/Disclaimer Legal Disclaimer Knightscope and www.knightscope.com are operated by Knightscope, Inc. Investment opportunities in the Reg A+ offering are not a public offering, are private placements, are subject to long hold periods, are illiquid investments and investors must be able to afford the loss of their entire principal. There is no guarantee that Knightscope will register its shares with the SEC or any stock exchange. Offers to buy or sell any security can only be made through official offering and subscription documents that contain important information about risks, fees and expenses. You should conduct your own due diligence including reviewing in detail the Offering Circular and consultation with a financial advisor, attorney, accountant, or other professional that can help you to understand the risks associated with the investment opportunity. Forward-Looking Statements This release may contain forward-looking statements regarding Knightscope’s proposed public listing of its securities and the timing thereof, projected business performance, operating results, financial condition and other aspects of the company, expressed by such language as “expected,” “anticipated,” “projected” and “forecasted.” These statements also include estimates of the pace of customer adoption of the company’s products, engineering developments and prototype capabilities. Please be advised that such statements are intentions or estimates only and there is no assurance that the results stated or implied by forward-looking statements will actually be realized by the company, or that the company will be able to consummate its planned goals (including without limitation, a public listing of its securities). Forward-looking statements may be based on management assumptions that prove to be wrong. The Company’s predictions may not be realized for a variety of reasons, including due to inability to raise a sufficient amount of funds, a lack of marketability for the company’s securities, failure of business operations, competition, customer sales cycles, and engineering or technical issues, among others. The Company and its business are subject to substantial risks and potential events beyond its control that would cause material differences between predicted results and actual results, including the company incurring operating losses and experiencing unexpected material adverse events. Corporate Communications InvestorBrandNetwork (IBN)Los Angeles, Californiawww.InvestorBrandNetwork.com310.299.1717 OfficeEditor@InvestorBrandNetwork.com
4 minutes ago
Business Wire
Nearly 2,500 Acres of Land Returned to the Yurok Tribe, Adding to 34,000 Acre Contiguous Yurok Community Forest
The Yurok Tribe announced that 2,424 acres of privately owned timberlands in NoCal will be transferred to the Tribe for permanent ownership.
4 minutes ago
GlobeNewswire
Vaccinex Announces Publication of Results from CLASSICAL-Lung Phase 1b/2 Clinical Trial in Non-Small Cell Lung Cancer in the Peer-Reviewed Journal Clinical Cancer Research
CLASSICAL-Lung study evaluated pepinemab in combination with the checkpoint inhibitor BAVENCIO® for the treatment of non-small cell lung cancerROCHESTER, N.Y., April 21, 2021 (GLOBE NEWSWIRE) -- Vaccinex, Inc. (Nasdaq: VCNX), a clinical-stage biotechnology company pioneering a differentiated approach to treating cancer and neurodegenerative disease through the inhibition of SEMA4D, today announced the publication of results from the company’s CLASSICAL-Lung clinical trial in the journal Clinical Cancer Research, a publication of the American Association for Cancer Research (AACR). CLASSICAL-Lung was a Phase 1b/2 trial evaluating the company’s lead clinical candidate, pepinemab, in combination with the immune checkpoint inhibitor BAVENCIO® (avelumab) for the treatment of non-small cell lung cancer (NSCLC). The paper, entitled, “A Phase 1b/2 Study of Pepinemab in Combination with Avelumab in Advanced Non-Small Cell Lung Cancer,” presents data showing that pepinemab is clinically active when combined with BAVENCIO® and was well tolerated, with no identified safety concerns. The combination appeared to halt or reverse tumor progression (partial response or stable disease) in a subset of both immunotherapy naïve patients, including patients with often difficult to treat PD-L1–negative or PD-L1–low tumors, and some patients with primary or acquired resistance to prior single-agent anti-PD-1/L1 therapy. Among 21 evaluable immunotherapy naïve patients, most of whom had negative or low tumoral expression of the PD-L1 biomarker, five patients experienced partial responses, four patients evidenced clinical benefit at or greater than one year, and the disease control rate (DCR) was 81%. Notably, the objective response rate (ORR) with the combination therapy was higher than previously reported for single agent avelumab in the PD-L1 negative / low population. Among 29 evaluable patients who previously experienced disease progression during or following anti-PD-1/L1 immunotherapy, the subsequent combination treatment resulted in a DCR of 59%, including two partial responses and seven patients with durable clinical benefit of at least 23 weeks. Finally, exploratory biomarker analysis from biopsies demonstrated improved penetration of killer CD8+ T cells into the tumor. Dr. Maurice Zauderer, President and CEO of Vaccinex, stated, “The results of the CLASSICAL-Lung study support our hypothesis that adding pepinemab to a checkpoint inhibitor for the treatment of NSCLC can shift the tumor microenvironment toward anti-tumor immunity and away from immunosuppression. This appears to enhance the efficacy of checkpoint inhibition, even in some patients who did not respond to prior anti-PD-1/L1 therapies. We are very pleased to have the full data set published in this prestigious peer-reviewed medical journal and look forward to the continued development of this promising combination for the treatment of NSCLC. We are particularly pleased to shortly begin a new study of the combination of pepinemab and Keytruda® (pembrolizumab) in front-line Head & Neck cancer.” The publication is now available electronically at: https://clincancerres.aacrjournals.org/content/early/2021/04/06/1078-0432.CCR-20-4792 About the CLASSICAL – Lung Clinical Trial The design of the trial consisted of a 12-subject dose escalation phase to determine the recommended Phase 2 dose of pepinemab in combination with avelumab, followed by a 50-subject dose expansion phase. The study included a total of 21 evaluable patients who were immunotherapy naïve and 32 patients who were refractory or resistant to prior treatment with immune checkpoint inhibitors (predominantly anti–PD-1). The primary objective was to assess safety and tolerability. Secondary objectives included evaluation of efficacy, immunogenicity, and PK/PD. An exploratory objective was to identify candidate biomarkers of activity. For more information: NCT03268057 Forward Looking Statements To the extent that statements contained in this presentation are not descriptions of historical facts regarding Vaccinex, Inc. (“Vaccinex,” “we,” “us,” or “our”), they are forward-looking statements reflecting management’s current beliefs and expectations. Such statements include, but are not limited to, statements about our plans, expectations and objectives with respect to the results and timing of our clinical trials of pepinemab in various indications, the use and potential benefits of pepinemab in Huntington’s and Alzheimer’s disease and other indications, and other statements identified by words such as “may,” “will,” “appears,” “expect,” “planned,” “anticipate,” “estimate,” “intend,” “hypothesis,” “potential,” “advance,” and similar expressions or their negatives (as well as other words and expressions referencing future events, conditions, or circumstances). Forward-looking statements involve substantial risks and uncertainties that could cause the outcome of our research and pre-clinical development programs, clinical development programs, future results, performance, or achievements to differ significantly from those expressed or implied by the forward-looking statements. Such risks and uncertainties include, among others, uncertainties inherent in the execution, cost and completion of preclinical and clinical trials, uncertainties related to regulatory approval, risks related to our dependence on our lead product candidate pepinemab, the impact of the COVID-19 pandemic, and other matters that could affect our development plans or the commercial potential of our product candidates. Except as required by law, we assume no obligation to update these forward-looking statements. For a further discussion of these and other factors that could cause future results to differ materially from any forward-looking statement, see the section titled “Risk Factors” in our periodic reports filed with the Securities and Exchange Commission (“SEC”) and the other risks and uncertainties described in our Form 10-K dated March 9, 2020 and subsequent filings with the SEC. Investor ContactJeremy FefferLifeSci Advisors, LLC212-915-2568jeremy@lifesciadvisors.com
4 minutes ago
GlobeNewswire
LAWSUIT FILED: FibroGen, Inc. Sued for Violations of the Federal Securities Laws; Investors Should Contact Block & Leviton
BOSTON, April 21, 2021 (GLOBE NEWSWIRE) -- Block & Leviton LLP (www.blockleviton.com), a national securities litigation firm, announces that a lawsuit for violations of the federal securities laws has been filed against FibroGen, Inc. (NASDAQ: FGEN) and certain of its executives. Investors should contact Block & Leviton to learn more via our case website, by email at cases@blockleviton.com, or by phone at (617) 398-5600. The deadline to move for appointment as lead plaintiff is June 11, 2021. After the markets closed on April 6, 2021, FibroGen admitted that prior disclosures regarding its safety analyses from the roxadustat Phase 3 program included post-hoc changes to the stratification factors. FibroGen said it would conduct a “comprehensive internal review to ensure” that such errors do not occur again. On this news, FibroGen’s shares fell $14.90 per share, or approximately 43%, to close at just $19.74 per share on April 7, 2021. If you purchased or acquired FibroGen securities between November 8, 2019 and April 6, 2021, you are strongly encouraged to contact the nationally-recognized law firm Block & Leviton LLP (www.blockleviton.com) at (617) 398-5600, via email at cases@blockleviton.com, or to visit our website for information on the case. The deadline to move the Court to be appointed lead plaintiff is June 11, 2021. A class has not yet been certified, and until a certification occurs, you are not represented by an attorney. If you choose to take no action, you can remain an absent class member. Block & Leviton LLP is a firm dedicated to representing investors and maintaining the integrity of the country's financial markets. The firm represents many of the nation's largest institutional investors as well as individual investors in securities litigation throughout the United States. The firm's lawyers have recovered billions of dollars for its clients. This notice may constitute attorney advertising. CONTACT:BLOCK & LEVITON LLP260 Franklin St., Suite 1860Boston, MA 02110Phone: (617) 398-5600Email: cases@blockleviton.comSOURCE: Block & Leviton LLPwww.blockleviton.com
4 minutes ago
Business Wire
Merlin Cyber Launches FedRAMP Managed Service to Accelerate SaaS Companies’ Ability to Pursue $200B Public Sector IT Market
Merlin Cyber today launched Constellation GovCloud™, a managed service that is designed to accelerate FedRAMP authorization for SaaS companies.
4 minutes ago
GlobeNewswire
Replimune Appoints Genentech Global Oncology Franchise Head Sushil Patel, Ph.D. as Chief Commercial Officer
WOBURN, Mass., April 21, 2021 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (Nasdaq: REPL), a biotechnology company developing oncolytic immuno-gene therapies derived from its Immulytic™ platform, today announced the strengthening of its executive team with the appointment of Sushil Patel, Ph.D. as Replimune’s Chief Commercial Officer effective May 3, 2021. Sushil joins from Genentech, a member of the Roche Group, where he was global oncology franchise head for lung cancer, skin cancer and rare / agnostic tumor types and was previously lifecycle leader and “CEO for the molecule” in lung cancer for the multi-billion-dollar checkpoint blockade drug Tecentriq. “We are thrilled to welcome Sushil to our leadership team,” said Philip Astley-Sparke, Chief Executive Officer of Replimune. “Sushil brings a wealth of experience in immuno-oncology and an incredible track record of success in defining and implementing launch strategies. He is well suited to both spearhead the development of Replimune’s commercial capabilities and help guide our indication expansion and prioritization strategy as we seek to expedite the development of our pipeline to benefit as many patients as possible.” Sushil Patel commented, “Replimune’s broad pipeline of oncolytic immuno-gene therapies could become the next cornerstone of immuno-oncology treatment regimens. With RP1 in two registration-directed trials in CSCC and melanoma, it is now time to build an innovative and comprehensive commercial strategy and assemble a world-class team to advance these first-in-class therapies to patients. I am excited to be joining such a dynamic organization and look forward to doing my part to deliver on the full promise of the Company’s leading immuno-oncolytic platform.” As Chief Commercial Officer, Sushil will lead Replimune’s commercial team including launch readiness initiatives and play a key role in the development and execution of the Company’s “go to market” strategy. Sushil brings more than 20 years of oncology experience with pertinent skills in strategy, US and international oncology marketing and sales, and clinical development. He most recently served as Franchise Head in Global Product Strategy for Genentech. In this role, he was responsible for directing the company’s lung and skin cancer franchise with responsibility for multiple blockbuster drugs, generating in excess of $3.5 billion in annual global sales. Prior to his career in biotechnology, he worked as a strategic management consultant and at IMS Health in their Pharma Strategy Group. Sushil received a Doctor of Philosophy in Molecular Biology and a Master of Sciences in Biotechnology, both from the Imperial College of Science Technology and Medicine, University of London. In connection with his appointment, Replimune will grant Sushil a stock option to purchase 125,000 shares of its common stock with an exercise price equal to the closing price of Replimune’s common stock on the grant date. The stock option will have a 10-year term and will vest over four years, with 25% of the underlying shares vesting on the one-year anniversary of the grant date and the remainder vesting monthly for three years thereafter. Replimune will also grant Sushil restricted stock units, representing 88,333 shares of its common stock. The restricted stock units will vest in approximately four equal annual installments beginning on May 15, 2022. The stock option and restricted stock units (the “equity awards”) will be granted subject to and effective upon the commencement of Sushil’s employment on May 3, 2021. The equity awards will be granted outside of Replimune’s 2018 Equity Incentive Plan, but will have terms and conditions consistent with those set forth under the plan. The equity awards were approved by the compensation committee of Replimune’s board of directors in reliance on the employment inducement exception under Nasdaq Listing Rule 5635(c)(4). About Replimune Replimune Group, Inc., headquartered in Woburn, MA, was founded in 2015 to develop the next generation of oncolytic immune-gene therapies for the treatment of cancer. Replimune is developing novel, proprietary therapeutics intended to improve the direct cancer-killing effects of selective virus replication and the potency of the immune response to the tumor antigens released. Replimune’s Immulytic™ platform is designed to maximize systemic immune activation, in particular to tumor neoantigens, through robust viral-mediated immunogenic tumor cell killing and the delivery of optimal combinations of immune-activating proteins to the tumor and draining lymph nodes. The approach is expected to be highly synergistic with immune checkpoint blockade and other approaches to cancer treatment across a broad range of cancers. Replimune intends to progress these therapies rapidly through clinical development in combination with other immuno-oncology products with complementary mechanisms of action as well as in standalone indications. For more information, please visit www.replimune.com. Forward Looking Statements This press release contains forward looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, including statements regarding the advancement of our clinical trials, our plans to initiate new clinical trials, our goals to develop and commercialize our product candidates, and other statements identified by words such as “could,” “expects,” “intends,” “may,” “plans,” “potential,” “should,” “will,” “would,” or similar expressions and the negatives of those terms. Forward-looking statements are not promises or guarantees of future performance, and are subject to a variety of risks and uncertainties, many of which are beyond our control, and which could cause actual results to differ materially from those contemplated in such forward-looking statements. These factors include risks related to our limited operating history, our ability to generate positive clinical trial results for our product candidates, the costs and timing of operating our in-house manufacturing facility, the timing and scope of regulatory approvals, changes in laws and regulations to which we are subject, competitive pressures, our ability to identify additional product candidates, political and global macro factors including the impact of the coronavirus as a global pandemic and related public health issues, and other risks as may be detailed from time to time in our Annual Reports on Form 10-K and Quarterly Reports on Form 10-Q and other reports we file with the Securities and Exchange Commission. Our actual results could differ materially from the results described in or implied by such forward-looking statements. Forward-looking statements speak only as of the date hereof, and, except as required by law, we undertake no obligation to update or revise these forward-looking statements. Investor Inquiries Chris BrinzeyWestwicke, an ICR Company339.970.2843chris.brinzey@westwicke.com Media InquiriesLissete SteeleVerge Scientific Communications202.930.4762lsteele@vergescientific.com
4 minutes ago
Business Wire
ACI Worldwide Recognized by Central Banking Magazine for Real-Time Payments Services
ACI Worldwide (NASDAQ: ACIW), a leading global provider of real-time digital payment software and solutions, today announced that it has been recognized by Central Banking Magazine with its 2021 Central Banking Award for Payments Services. The award highlights ACI as an important provider of real-time digital payments software, helping banks and small companies connect to core central bank infrastructure.
4 minutes ago
GlobeNewswire
Adverum Mails Letter to Stockholders Highlighting World-Class Board of Directors Overseeing Successful ADVM-022 Commercial Launch
Adverum Slate Background Adverum Slate Background Adverum Board Matrix Adverum Board Matrix Sonic’s Nominees Lack Experience and Qualifications to Advance Adverum’s Commercialization Progress or Deliver Global Access to Vision-Saving Gene Therapy Urges Stockholders to Vote the WHITE Proxy Card “FOR” ALL of Adverum’s Three Highly Qualified, Diverse and Independent Directors: Dawn Svoronos, Reed V. Tuckson, M.D. and Thomas Woiwode, Ph.D. REDWOOD CITY, Calif., April 21, 2021 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage gene therapy company targeting unmet medical needs in ocular and rare diseases, today announced that it is mailing a letter to stockholders in connection with its 2021 Annual Meeting of Stockholders (“Annual Meeting”) urging them to vote the WHITE proxy card “FOR” ALL of Adverum’s three highly qualified directors standing for election - Dawn Svoronos, Reed V. Tuckson, M.D. and Thomas Woiwode, Ph.D. The Annual Meeting will be held on May 12, 2021 and Adverum stockholders of record at the close of business on April 14, 2021 are entitled to vote at the Annual Meeting. The full text follows and can be found on the investor section of the Company's website at https://investors.adverum.com/shareholder-services/annual-meeting. April 21, 2021 Dear Fellow Stockholder, Adverum has taken significant and deliberate steps in recent years to establish a world-class, highly qualified, independent and diverse Board of Directors. Your Board has the right mix of skills and experience as we move toward commercialization of ADVM-022, our one-time, in-office advanced gene therapy for the treatment of wet age-related macular degeneration (“wet AMD”) and diabetic macular edema (“DME”), which are two of the leading causes of blindness impacting nine million people globally. As Adverum has progressed to late stage development in 2021, identifying the right talent and skillsets required to bring ADVM-022 to millions of patients worldwide, so too has the quality of our Board. Simply put, our Board is extremely well-positioned as we accelerate our development and commercialization strategy and drive value for our stockholders. VOTE THE WHITE PROXY CARD “FOR” ALL OF ADVERUM’S THREE HIGHLY QUALIFIED, DIVERSE AND INDEPENDENT DIRECTORS: DAWN SVORONOS, REED V. TUCKSON, M.D. AND THOMAS WOIWODE, PH.D. Meet Your Board Nominees A graphic accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/a1385167-dcab-4192-9443-02f9602e567e OUR THREE DIRECTOR CANDIDATES BRING CONSIDERABLE DIVERSITY OF THOUGHT AND CRITICAL SECTOR EXPERTISE TO SUPPORT A SUCCESSFUL COMMERCIAL LAUNCH OF ADVM-022 Not only is Adverum’s Board slate ideally qualified to advance our strategy towards a Biologics License Application filing in 2024, we are committed to continuous improvement. In the last two years, the Board has appointed seven new independent directors, three in May 2019 and four thereafter, including Ms. Svoronos and Dr. Tuckson in December 2020 and February 2021, respectively. And we’re not stopping there. The Board is continuing its refreshment efforts and has already begun a process to recruit a high-quality independent director with commercial gene therapy experience to be named in 2021. As part of this process, we have been actively engaging with our stockholders about top candidates and already interviewed candidates to fill this slot. A vote on the WHITE proxy card is a vote FOR: A graphic accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/0d7b3f1e-48ab-46d4-97c6-a58a929f1dd0 SONIC’S NOMINEES ARE NOT ADDITIVE TO THE ADVERUM BOARD As you know, The Sonic Fund II, L.P. has proposed nominees that, if elected, together with its two designees appointed in 2019, would constitute more than half of the Board. Sonic’s nomination of three candidates for election to the Board is not in the best interest of our stockholders – their election would diminish the diversity and the needed skills and experience represented on our Board, and there is no reason to believe they would enhance our efforts to advance ADVM-022 toward commercialization and deliver global access to our vision-saving gene therapy. Not only would the resulting loss of Ms. Svoronos, Dr. Tuckson and Dr. Woiwode from your Board significantly harm our ability to generate value, we strongly believe that your Board’s current process to identify a new director with commercial gene therapy experience is superior to relying solely on input from one stockholder who is trying to control the Board. Importantly, Sonic has not presented any meaningful strategy or articulated any plan that would advance Adverum’s mission or increase value to our stockholders. Lawrence Kam, Sonic’s principal, has no drug development experience whatsoever and has done nothing other than disparage members of our team with no substantiation and has presented arbitrary ideas that would destroy stockholder value, including inferences that improved communication rather than scientific rigor and transparent presentation of data at peer-reviewed conferences is the solution. Put simply, Sonic is putting at risk Adverum’s laser focus on commercializing our gene therapy technology and credibility, even suggesting to reunite a leadership team that led Avalanche Biotechnologies, one of the two companies that merged in 2016 to form Adverum. Our stockholders should not allow Sonic to impede our momentum and threaten the development and eventual commercialization of the first mass market gene therapy product. This is all against the backdrop of Adverum making tremendous progress and already delivering meaningful stockholder value. Adverum has delivered five, three and two-year total stockholder return of 91%, 70% and 88% respectively, significantly outperforming gene therapy peers.1 Please protect your investment in Adverum and vote “FOR” ALL three of Adverum's nominees listed on the WHITE proxy card: Ms. Svoronos, Dr. Tuckson and Dr. Woiwode We are confident that Adverum’s Board and our 2021 nominees possess the expertise, operational and industry experience, knowledge and skills to support the continued execution of Adverum’s strategy and drive long-term stockholder value. Simply follow the easy instructions on the enclosed proxy card to vote by telephone, by internet or by signing, dating and returning the WHITE proxy card in the postage-paid envelope provided. Please disregard any green proxy card you get from Sonic. We appreciate your continued support. Sincerely, The Adverum Board of Directors AdvisorsCooley LLP and Skadden, Arps, Slate, Meagher & Flom LLP are serving as legal advisors, and Centerview Partners LLC is serving as financial advisor to Adverum. About Adverum BiotechnologiesAdverum Biotechnologies (Nasdaq: ADVM) is a clinical-stage gene therapy company targeting unmet medical needs in serious ocular and rare diseases. Adverum is advancing the clinical development of its novel gene therapy candidate, ADVM-022, as a one-time, intravitreal injection for the treatment of patients with wet age-related macular degeneration and diabetic macular edema. For more information, please visit www.adverum.com. Forward-looking StatementsStatements contained in this press release regarding the events or results that may occur in the future are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements include, but are not limited to, statements regarding Adverum’s expectations that it will submit a Biologics License Application in 2024 and that its commercial facility in Durham, North Carolina is expected to be production-ready by the end of 2023. Actual results could differ materially from those anticipated in such forward-looking statements as a result of various risks and uncertainties, which include risks inherent to, without limitation: Adverum’s novel technology, which makes it difficult to predict the time and cost of product candidate development and obtaining regulatory approval; the results of early clinical trials not always being predictive of future results; the potential for future complications or side effects in connection with use of ADVM-022, and the possibility of unexpected delays in the completion of its commercial facility in Durham, North Carolina. Risks and uncertainties facing Adverum are described more fully in Adverum’s Annual Report on Form 10-K for the year ended December 31, 2020 and any subsequent filings with the SEC under the heading “Risk Factors.” All forward-looking statements contained in this letter speak only as of the date on which they were made. Adverum undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made. Important InformationAdverum Biotechnologies, Inc. (“Adverum”) has filed a definitive proxy statement and form of associated WHITE proxy card with the U.S. Securities and Exchange Commission (the “SEC”) in connection with the solicitation of proxies for Adverum’s 2021 Annual Meeting (the “Proxy Statement”). Adverum, its directors and certain of its executive officers and employees will be participants in the solicitation of proxies from stockholders in respect of the 2021 Annual Meeting. Information regarding the names of Adverum’s directors, executive officers and employees and their respective interests in Adverum by security holdings or otherwise is set forth in the Proxy Statement. Details concerning the nominees of Adverum’s Board of Directors for election at the 2021 Annual Meeting are included in the Proxy Statement. BEFORE MAKING ANY VOTING DECISION, INVESTORS AND STOCKHOLDERS OF ADVERUM ARE URGED TO READ ALL RELEVANT DOCUMENTS FILED WITH OR FURNISHED TO THE SEC, INCLUDING THE ADVERUM’S DEFINITIVE PROXY STATEMENT AND ANY SUPPLEMENTS THERETO AND ACCOMPANYING WHITE PROXY CARD, BECAUSE THEY CONTAIN IMPORTANT INFORMATION. Investors and stockholders can obtain a copy of the Proxy Statement and other relevant documents filed by Adverum free of charge from the SEC’s website, www.sec.gov. Stockholders may also contact Innisfree M&A Incorporated with questions or requests for additional copies of the proxy materials by calling toll free at (877) 750-9496. 1 FactSet as of March 31, 2021; Gene Therapy peers reflect median of Abeona, AGTC, Amicus, AVROBIO, Gensight, Homology, Krystal, MeiraGTx, Orchard, Passage Bio, REGENXBIO, Rocket, Sangamo, Solid Biosciences, uniQure and Voyager. CONTACT: Investor Relations Contact Myesha Lacy Vice President, Investor Relations and Corporate Communications Adverum Biotechnologies, Inc. T: 650-649-1257 E: Or Scott Winter / Gabrielle Wolf Innisfree M&A Incorporated T: 212-750-5833 Media Contact Andrea Cohen Sam Brown Inc. T: 917-209-7163 E: Or Dan Moore Joele Frank, Wilkinson Brimmer Katcher T: 212-355-4449
4 minutes ago
GlobeNewswire
Anaqua Launches Business Innovation Suite to Help Organizations Boost Innovation Throughput
Business Innovation Suite connects R&D, business, and legal practitioners to support inventors and accelerate the generation and commercialization of intellectual propertyBOSTON, April 21, 2021 (GLOBE NEWSWIRE) -- Anaqua, the leading innovation and intellectual property management technology provider, today announces the launch of its Business Innovation Suite™ to support inventors and empower organizations to enhance and accelerate their innovation capabilities and processes. Offered as both part of Anaqua’s AQX® IP management platform or as a standalone product, the Business Innovation Suite serves all departments in an organization, especially Research & Development, Product Management, and Intellectual Property by facilitating cross-functional innovation aligned with the organization’s business strategy. “There are a number of studies that cover effective, as well as ineffective innovation processes,” said Vincent Brault, Senior Vice President of Product & Innovation at Anaqua. “Insufficient collaboration and the lack of rigor in assessing ideas are two obstacles frequently cited as impeding success. By launching the Business Innovation Suite, we are addressing this disconnect and empowering organizations with a solution that will improve collaboration, enable better and faster assessment of ideas, and help steer innovation to meet their business objectives.” Through the Business Innovation Suite, organizations can post and communicate current challenges, areas of interest, and goals to proactively align innovation with the strategic vision of the company. The platform also helps organizations get to market faster through capabilities that enable improved collaboration and enhanced decision-making processes to move the best submissions forward. Features include an easy-to-use custom branded portal to help capture and submit ideas, workspaces for ideation and collaboration, and a configurable review process and ratings for efficient decision-making. About Anaqua Anaqua, Inc. is a premium provider of integrated intellectual property (IP) management technology solutions and services. Its software solution, AQX, combines best practice workflows with big data analytics and tech-enabled services to create one intelligent environment designed to inform IP strategy, enable IP decision-making, and streamline IP operations. Today, more than 50% of the top 20 U.S. patent filers, top 20 global brands, and a growing number of law firms worldwide use Anaqua’s solutions. Over one million IP executives, attorneys, paralegals, administrators, and innovators in large and medium-sized companies use the platform for their IP management needs. The company’s global operations are headquartered in Boston, with offices across the U.S., Europe, and Asia. For additional information, please visit anaqua.com. Company Contact:Amanda HollisAssociate Director, Communications Anaqua 617-375-2626ahollis@Anaqua.com
4 minutes ago
Business Wire
Integrated Specialty Coverages (ISC) Launches New Vacant Property Program
Integrated Specialty Coverages ("ISC" or the "Company"), a leading, multi-line program administrator that builds end-to-end insurance products utilizing advanced artificial intelligence (AI) engineering and data analytics, today announced the launch of its exclusive new Vacant Property Program ("VPP"), designed to address the increasing number of vacant residential and commercial properties across the U.S., while providing owners flexible terms at competitive rates.
4 minutes ago
Business Wire
Massachusetts FQHC Telehealth Consortium Announces Launch of Phase II of Telemedicine Campaign with More Than $4.7M in Grants
The FQHC Telehealth Consortium launches Phase II of its campaign to greatly increase telemedicine capacity in Massachusetts’s community health centers
4 minutes ago

ALL ORDS

AUD/USD

ASX 200

OIL

GOLD

BTC-AUD

CMC Crypto 200

Get the latest business, economy and property news, delivered straight to you.

China Diplomat Warns Biden to Tread Carefully on Taiwan

Latest stories

Global Facilities Management Market Report 2021: Market to Reach $3 Trillion by 2027 - U.S. Market is Estimated at $417.7 Billion, While China is Forecast to Grow at 10.8% CAGR - ResearchAndMarkets.com

General James Mattis to Headline Cloud Security Alliance CISO Summit at RSA Conference 2021

Acrisure Creates Large Relationships Division

Global Granite, Marble and Stone Market Report 2021: Asia-Pacific - The Dominant and the Fastest Growing Crushed Stone Market Worldwide - ResearchAndMarkets.com

Excellthera and Ossium Health Announce a Collaboration to Advance Their Technologies and Platforms to Improve Human Health

Senzing One-Day Proof of Concept Finds Duplicate Data, Hidden Relationships

Global Transcatheter Pulmonary Valves Market to Reach $58.6 Million by 2027

Atlas Technical Consultants Awarded Engineering Services Contract with Texas Department of Transportation

Do You Need a Crypto Wallet to Store Your Bitcoin?

InvestorBrandNetwork Announces Gamechangers LIVE Interview with Knightscope Inc. Chairman and CEO William Santana Li

Nearly 2,500 Acres of Land Returned to the Yurok Tribe, Adding to 34,000 Acre Contiguous Yurok Community Forest

Vaccinex Announces Publication of Results from CLASSICAL-Lung Phase 1b/2 Clinical Trial in Non-Small Cell Lung Cancer in the Peer-Reviewed Journal Clinical Cancer Research

LAWSUIT FILED: FibroGen, Inc. Sued for Violations of the Federal Securities Laws; Investors Should Contact Block & Leviton

Merlin Cyber Launches FedRAMP Managed Service to Accelerate SaaS Companies’ Ability to Pursue $200B Public Sector IT Market

Replimune Appoints Genentech Global Oncology Franchise Head Sushil Patel, Ph.D. as Chief Commercial Officer

ACI Worldwide Recognized by Central Banking Magazine for Real-Time Payments Services

Adverum Mails Letter to Stockholders Highlighting World-Class Board of Directors Overseeing Successful ADVM-022 Commercial Launch

Anaqua Launches Business Innovation Suite to Help Organizations Boost Innovation Throughput

Integrated Specialty Coverages (ISC) Launches New Vacant Property Program

Massachusetts FQHC Telehealth Consortium Announces Launch of Phase II of Telemedicine Campaign with More Than $4.7M in Grants